MUC16 and ovarian carcinoma: In conclusion, we propose that in a hypoxic tumor microenvironment, target-antigen downregulation, EMT transformation, and VEGF-secretion cooperatively mediate resistance to MUC16 BITE-medicated cytotoxicity in epithelial ovarian cancer cells.